Wire · opportunities
Canada approves multiple denosumab and ustekinumab biosimilars as global competition grows
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 15 September 2026 · Fusion42 review
Health Canada approved multiple biosimilars for denosumab and ustekinumab in 2026, expanding treatment choices for osteoporosis, cancer-related bone conditions, and inflammatory diseases. This approval reflects growing global competition in biosimilars and aims to drive price reductions and improve patient access in Canada.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Health Canada approvals expand biosimilar entry points, opening pricing pressure and market access opportunities for founders targeting osteoporosis and inflammatory disease treatments. You must act fast to position your biosimilar or support product before provincial substitution policies shape uptake.
◆ Coverage
1 source · 15 Sep 2026
◆ Related on Wire
◆ Topics